Thermo Fisher Scientific Updates Customizable TaqMan SARS-CoV-2 Mutation Panel to Detect Delta and Lambda Variants
Excerpt from the Press Release:
CARLSBAD, Calif., Aug. 9, 2021 /PRNewswire/ — Thermo Fisher Scientific, the world leader in serving science, today announced it has updated its Applied Biosystems TaqMan SARS-CoV-2 Mutation Panel to detect the Delta and Lambda strains. First launched in March 2021, the research panel features a customizable menu of verified real-time PCR assays for identification of SARS-CoV-2 mutations.
The panel enables laboratories to track known mutations by selecting from a menu of over 50 assays designed to screen for different variants. The TaqMan SARS-CoV-2 Mutation Panel is highly scalable, allowing up to hundreds of samples to be run to identify one or multiple mutations so labs can scale their surveillance operations based on testing need.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?